- Home
- IMUX vs IMA Comparison
IMUX vs IMA Comparison
Compare IMUX & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMUX | IMA |
|---|---|---|
| Founded | 2016 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.2M | 65.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | IMUX | IMA |
|---|---|---|
| Price | $0.70 | $7.20 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 2 |
| Target Price | $6.00 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 1.4M | 41.2K |
| Earning Date | 02-26-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $800,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.51 | $5.70 |
| 52 Week High | $1.39 | $18.00 |
Technical Indicators
Market Signals| Indicator | IMUX | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 59.00 | 59.02 |
| Support Level | $0.57 | $6.65 |
| Resistance Level | $0.69 | $7.60 |
| Average True Range (ATR) | 0.06 | 0.47 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 85.40 | 89.36 |
Price Performance
Historical ComparisonAbout IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.